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Introduction: Lung cancer is the leading cause of cancer-related
mortality and requires more effective molecular markers of progno-
sis and therapeutic responsiveness. Special AT-rich binding protein
1 (SATB1) is a global genome organizer that recruits chromatin
remodeling proteins to epigenetically regulate hundreds of genes
in a tissue-specific manner. Initial studies suggest that SATB1
overexpression is a predictor of poor prognosis in breast cancer, but
the prognostic significance of SATB1 expression has not been
evaluated in lung cancer.
Methods: A cohort of 257 lung cancers was evaluated by immuno-
histochemistry. Epigenetic silencing of SATB1 was examined in cell
lines by 5-Aza 2-deoxycytidine and trichostatin A treatment, and
chromatin immunoprecipitation.
Results: Significant loss of SATB1 expression was found in squa-
mous preinvasive lesions (p  0.04) and in non-small cell lung
cancers (p  0.001) compared with matched normal bronchial
epithelium. Loss of SATB1 independently predicted poor cancer-
specific survival in squamous cell carcinomas (SCCs; hazard ratio:
2.06, 95% confidence interval: 1.2–3.7, p  0.016). Treatment of
lung cancer cell lines with the histone deacetylase inhibitor tricho-
statin A resulted in up-regulation of SATB1. SATB1 was associated
with a decrease in the active chromatin mark acetylated histone
H3K9 and an increase in the repressive polycomb mark trimethy-
lated H3K27 in a SCC cell line relative to a normal bronchial
epithelial cell line.
Conclusions: This is the first study showing that SATB1 expression is
lost in early preinvasive squamous lesions and that loss of SATB1 is
associated with poor prognosis in lung SCC. We hypothesize that the
SATB1 gene is epigenetically silenced through histone modifications.
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Lung cancer is the most frequent cancer worldwide with thehighest cancer-related mortality.1 This represents a major
public health problem, with lung cancer accounting for 1.2
million deaths globally each year.2 Therapeutic interventions
have had little impact on the prognosis of non-small cell lung
cancer (NSCLC) and small cell lung cancers (SCLCs), which
have 5-year survival rates of 15% and 5%, respectively.1,3
Lung cancer is histologically and phenotypically heteroge-
neous, and genetic markers that can further stratify tumors
into prognostically relevant or effective treatment subgroups
are greatly needed. The poor prognosis may improve with a
greater understanding of the molecular basis of the disease,
with a focus on molecular markers of risk that may lead to
improved detection or treatment strategies.
Lung cancer develops through the accumulation of
genetic and epigenetic abnormalities, in preinvasive lesions
to invasive lung cancer.4 One abnormality detected in early
squamous preinvasive lesions is widespread histone modifi-
cations, such as loss of H4K20 trimethylation.5 Abnormal
modifications to the histone code play an important role in
lung cancer tumorigenesis and are predictive of prognosis.5,6
Special AT-rich binding protein 1 (SATB1) is a tissue-specific
chromatin remodeling protein that regulates the epigenetic or-
ganization of multiple genes by region-specific histone modifi-
cations, which are dictated by the binding of SATB1 to specific
ATC-rich DNA sequences.7–9 SATB1 regulates hundreds of
genes simultaneously by tethering specific loop regions of DNA
to the nuclear matrix8 and recruiting other chromatin remodeling
proteins to regulate chromatin structure and gene expression
over long distances.10,11
Initial studies suggest that SATB1 overexpression is as-
sociated with tumor progression and metastasis in breast can-
cer,10,12 where it is an independent predictor of poor prognosis.10
Nevertheless, independent validation of the prognostic role of
SATB1 expression does not support this finding.12–14 The first
breast cancer study10 showed that SATB1 expression directs
epigenetic modifications resulting in up-regulation of metastasis-
associated genes, while down-regulating tumor suppressor
genes. By binding to base unpairing regions of DNA, SATB1 is
able to act as a docking station for specific chromatin remodel-
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ing proteins and transcription factors to coordinate chromatin
architecture and nucleosome positioning11,15–17 and regulate the
expression of more than 10% of all genes.17,18 Therefore, it can
be hypothesized that disruption of SATB1 may also result in
major changes in gene expression patterns that could contribute
to cancer.
SATB1 has also been implicated in other cancers. In
two studies of gastric cancer, increased SATB1 expression
was found to be an independent adverse prognostic fac-
tor.19,20 In addition, SATB1 was significantly overexpressed
in a cohort of 80 laryngeal squamous cell carcinomas (SCC)
compared with normal mucosa.21
A microarray study comparing gene expression in the
lungs of Myf5-/-:Myod-/- mouse embryos revealed that SATB1
was down-regulated and was assumed to play a role in pulmo-
nary development and possibly in the differentiation of the
alveolar epithelium.22 Another study investigating messenger
RNA (mRNA) expression of SATB1 in NSCLC found a 13-fold
increase in SATB1 expression relative to normal lung23; how-
ever, peripheral lung alveoli and bronchial epithelium were
pooled in the normal lung sample. In addition, using the Onco-
mine Research Database, three microarray studies24–26 were
identified which showed significant down-regulation of SATB1
in lung cancer compared with normal lung, where no distinction
was made between peripheral alveoli and bronchial epithelium.
Because of the distinct morphological and functional nature of
both types of lung tissue, careful examination of SATB1 expres-
sion in both normal peripheral lung alveoli and bronchial epi-
thelium is warranted. Clarification of SATB1 protein expression
in SCLC and in the histological subtypes of NSCLC is also
needed.
SATB1 is located at chromosome 3p, a region which is
frequently associated with loss of heterozygosity and gene
promoter hypermethylation in NSCLCs.27 Chromosome 3p
alterations are some of the most frequent and earliest molec-
ular abnormalities in lung cancer.28–30 We have previously
described concordant methylation of several chromosome 3p
genes in NSCLC,31 which may be the consequence of a
long-range epigenetic effect.29 Therefore, we hypothesized
that SATB1 alteration may also be significant in lung cancer
and analyzed SATB1 expression in a cohort of 257 patients.
We show that, in contrast to breast cancer and gastric cancer,
SATB1 is significantly down-regulated or lost in squamous
preinvasive lesions, NSCLC tumors, and metastases. Loss of
SATB1 expression is also a marker of poor survival, inde-
pendent of American Joint Committee on Cancer (AJCC)
stage and lymph node status in SCCs. Furthermore, we show
that SATB1 is enriched with repressive histone modifications
in a SCC cell line suggesting that SATB1 may be epigeneti-
cally silenced in cancer.
PATIENTS AND METHODS
Cell Lines, Quantitative Polymerase Chain
Reaction, and Western Blot Analysis
The following cell lines were obtained from ATCC
(Manassas, VA) and grown according to recommendations:
H1299 (metastatic NSCLC), H1975 (adenocarcinoma [ADC]),
H292 (mucoepidermoid carcinoma), H358 (bronchioalveolar
carcinoma), H427 (ADC), H460 (large cell carcinoma), H520
(SCC), A549 (ADC), H187 (SCLC), NL20 (normal bronchial
epithelial cell line), and MDA-MB-231 (breast cancer cell line).
Total RNA was harvested from cell cultures using the RNeasy
Mini kit (Qiagen, Valencia, CA), incorporating DNase I treat-
ment (Qiagen). Complementary DNA synthesis was performed
using the TaqMan Gold RT-PCR kit (Applied Biosystems,
Foster City, CA) and the ABI 7900 Real-Time PCR system
(Applied Biosystems). SATB1 (Accession No. NM 002971.3)
primers used for quantitative polymerase chain reaction (qPCR)
were forward 5 CAT GTT CCA GCA GAG CAG ATT CAG
3 (3491–3514), reverse 5 CAC CGT GGG TTG CCG TGG 3
(3628–3611), and probe 5 d FAM-CCACAGCAGCAGCCA
CAG ACA GGC CC-BHQ-1 3. TaqMan assays were used
for the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
reference gene (Applied Biosystems). qPCRs were performed
in triplicate for at least three separate cultures per cell line.
For Western blot analysis, lysates from three separate
cultures for each cell line were prepared using RIPA buffer
supplemented with protease inhibitors: 1 mM phenylmethylsul-
fonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, and 0.1
mM sodium orthovanadate (Sigma-Aldrich, St Louis, MO).
Equivalent amounts of protein were subjected to sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
using polyvinylidene difluoride membranes (PVDF, Millipore,
Bedford, MA) to electro blot. Mouse anti-SATB1 monoclonal
antibody (611182, BD Biosciences, Franklin Lakes, NJ) 1:250
was used for Western blotting with mouse antiglyceraldehyde
3-phosphate dehydrogenase monoclonal antibody
(AM4300, Ambion, Austin, TX) 1:10,000, used as a ref-
erence gene. Western blots were scanned and densitometry
performed using Image J.32
Patient Cohort
Lung tissue samples were obtained from patients
treated at the Royal Prince Alfred Hospital, Sydney, Austra-
lia, between 1996 and 2002. Surgery was performed by the
one cardiothoracic surgeon (B.C.M.). Ethical approval for the
study was obtained from the Royal Prince Alfred Ethics
Review Committee (X02-0216 and X06-0167), granted with
a specific waiver of consent, with all tissue specimens ana-
lyzed anonymously. Only lung cancer-specific deaths were
included in the survival analysis. The cohort totaled 257
patients and included 14 patients with SCLC (5%) and 243
patients with stages I to IV NSCLCs (95%). Female patients
(95) made up 37% of the cohort and males (162) 63%.
Median age at diagnosis was 67 years (range: 37–87 years),
and median survival time was 37 months. Smoking history
was available for 196 patients of which 36 (18%) were
current smokers, 149 (76%) were exsmokers, and 11 (6%)
had no history of smoking. None of the patients received
adjuvant chemotherapy. Histological tumor subtypes were
assessed using the World Health Organization classifica-
tion,33 and within the NSCLCs, there were 107 (44%) ADCs
(including 16 [7%] bronchioloalveolar carcinomas [BACs]),
42 (17%) large cell carcinomas (LCCs), 7 (3%) large cell
neuroendocrine carcinomas (LCNECs), and 87 (36%) SCCs.
NSCLC tumors were staged using the AJCC tumor, node and
metastasis (TNM) classification classification.34 The cohort
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consisted of 151 (59%) stage I, 81 (32%) stage II, 19 (7%)
stage III, and 6 (2%) stage IV tumors. Forty-one patients with
regional lymph node metastases were included in the cohort.
Precursor lesions were also assessed when available, and
there were 27 cases of bronchial squamous epithelial meta-
plasia, 3 with low-grade dysplasia, and 11 cases of bronchial
SCC in situ. Follow-up information of at least 5 years was
available for this study.
Tissue Microarray Samples and
Immunohistochemistry Staining
Tissue microarrays were constructed using 2 to 4 tissue
cores of normal bronchial epithelium obtained from bronchi
or terminal bronchioles, 1 to 2 tissue cores of normal periph-
eral lung alveoli, and 3 to 6 tumor cores, per patient. Each
core was 1 mm in diameter and was selected from areas
previously marked by a specialist lung pathologist (W.A.C.)
as the most representative. Monoclonal mouse anti-SATB1
(611182, BD Biosciences) was used for immunohistochem-
istry. Antigen retrieval was performed with Dako buffer pH
9.0 (s2367, Dako, Carpentaria, CA) at 125°C for 5 minutes in
a Pascal pressure chamber (Dako), and the primary antibody
was incubated for 60 minutes at 1:20 dilution. The Envision
FLEX system (Dako) was used as a secondary antibody.
Mouse IgG1 was included as a negative control and normal
peripheral lung alveoli as a negative tissue control. Spleen
and normal bronchial epithelium were used as positive con-
trols. SATB1 staining was also confirmed in breast cancer
tissue with normal breast staining negatively for SATB1
expression (data not shown). SATB1 expression was evalu-
ated by estimating the average percentage of cells stained
positively. Staining was evaluated independently by C.I.S.
and a specialist lung pathologist W.A.C., without knowledge
of the patient’s clinical details, and the average of the two
percentages was used for analysis. Significant discrepancies
were reviewed before reaching a consensus. SATB1 expres-
sion data were dichotomized to positive or negatively stained,
with positively stained tissue set at a threshold of 5% of
cells stained positively. This threshold was arrived at, as
percentages of 5% were not accurately indicative of posi-
tive staining. This cutoff resulted in 119 patients with less
than 5% and 139 patients with 5% SATB1 expression. The
patient cohort contained insufficient examples of ADC pre-
invasive lesions, therefore only squamous preinvasive lesions
were analyzed.
Treatment of Cell Lines with 5-Aza
2-Deoxycytidine and Trichostatin A
A549 and NCI-H520 cell lines were seeded at 1  105
cells/ml in 100 mm culture dishes and prepared for each
treatment in triplicate. After 24 hours, the cells were treated
with either 5 M 5-Aza 2-deoxycytidine (5-AzaC, Sigma-
Aldrich, St Louis, MO) (for 24 hours, then fresh medium for
48 hours) or trichostatin A (TSA, Sigma) at 50, 100, or 200
nM concentrations for 48 hours. The equivalent volume of
ethanol was added to mock control cultures. For cotreatment
of cells with 5-AzaC and TSA, 5-AzaC was added initially
for 24 hours, after which it was removed and TSA added for
an additional 48 hours. After treatment, the cells were har-
vested for RNA analysis.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were
carried out with normal NL20 and NCI-H520 SCC cells using
the EZ-Magna ChIP kit (Millipore) according to the manu-
facturers instructions. Formaldehyde-crosslinked chromatin
was sonicated and immunoprecipitated with antibodies to
histone H3K9Ac (Millipore no. 06-599), histone H3K27Me3
(Millipore no. 07-449) and Rabbit IgG (Jackson ImmunoRe-
search, West Grove, PA, no. 011-000-120) as a control. ChIP
experiments were performed in duplicate. DNA enrichment
was quantified using SYBR green (Applied Biosystems)
real-time qPCR in triplicate. ChIP primers include SATB1
(Accession No. NT 022517.18) F: 5 GTT TTA ATC CCC
ATC CCT TTT CCG CC 3 (18406963-18406938) and SATB1
R: 5 GTC CGG GGA ACG GGA GCG AGC GA 3
(18406803-18406825). Internal control primers:MYOD (Acces-
sion No. NT 009237.18) F: 5 CCG CCT GAG CAA AGT
AAA TGA 3 (17681689–17681709),MYOD R: 5 GGC AAC
CGC TGG TTT GG 3 (17681763–17681747),GAPDH control
primers (Acession No. NT009759.16) F: 5TCG ACA GTC
AGC CGC ATC R 3(6583701–6583719), and R: 5CTA GCC
TCC CGG GTT TCT CT 3 (6583769–6583750). For each
chromatin sample, the average Ct value was obtained for the
immunoprecipitated material and for the input chromatin. The
difference in Ct values (delta Ct) reflects the difference in
the amount of material that was immunoprecipitated relative to
the amount of input chromatin or the internal control genes
GAPDH and MYOD as described in ABI PRISM 7700 Se-
quence Detection System User Bulletin no 2, P/N 4303859.
Statistical Analysis
SATB1 expression between cell lines, and between
primary tumors and normal tissue were compared with Stu-
dent’s t test (two sided). Associations between SATB1 ex-
pression and clinicopathological parameters were compared
with Fisher’s exact test (two sided). The Kaplan-Meier log-
rank and Cox proportional regression models were used for
survival analysis, determining hazard ratios (HRs) with 95%
confidence intervals (CIs). Statistical analyses were per-
formed with Stata/SE 9.2 (Stata Corp., College Station, TX)
and SPSS software (IBM, Chicago, IL). p values of less than
0.05 were considered statistically significant.
RESULTS
Differential SATB1 Expression in Normal Lung
and Lung Cancer Cell Lines
SATB1 expression was analyzed in eight NSCLC cell
lines (H1299, H1975, H292, H358, H427, H460, H520, and
A549), a SCLC cell line (H187), and a normal bronchial
epithelial cell line (NL20) at the mRNA transcript level by
real-time qPCR analysis (Figure 1A). The MDA-MB-231
breast cancer cell line was included as a positive control,
which confirmed relative mRNA and protein expression of
SATB1. The majority of NSCLC cell lines (6/8) had signif-
icantly reduced expression of SATB1 relative to the normal
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bronchial epithelial cell line NL20 (p  0.042). The SCLC
cell line showed significantly increased expression of SATB1
relative to NL20 cells (p  0.022). The same trend of
expression was observed at the protein level, with the major-
ity of NSCLC cell lines (5/8) showing significantly lower
abundance of SATB1 expression relative to NL20 cells (Fig-
ures 1B, C, p  0.044). The SCLC cell line showed signifi-
cantly more abundant expression of SATB1 protein relative
to NL20 cells (p  0.001).
SATB1 Nuclear Expression is Decreased in
Primary NSCLC Tumors
SATB1 is a matrix attachment binding protein and is
functional in the nucleus. Immunohistochemical analysis of
nuclear SATB1 expression was performed in 257 lung can-
cers and matching normal bronchial and peripheral lung
alveoli tissues. SATB1 expression was absent in peripheral
lung alveoli (Figure 2D). The majority of patients (96%)
showed nuclear SATB1 expression in the pseudostratified
columnar epithelium of normal bronchi or terminal bronchi-
oles (Figures 2A and 3B) but not homogeneously in all cells.
On average, 28.7% of normal bronchial epithelial cells
stained positive for SATB1 in the nucleus (Figure 2M). The
level of SATB1 nuclear expression was significantly de-
creased in cancer tissue in all NSCLC subtypes and lymph
node metastases (Figure 2M), where the average number of
cells showing SATB1 nuclear expression was 16.9% in LCC
(p  0.001), 13.7% in SCC (p  0.001), and 7.1% in ADC
(p  0.001). There was no significant difference between
SCLC (p  0.574), SCLC metastases (p  0.380), and
normal bronchial epithelium (Figure 2M). When SATB1
expression was dichotimized to  or less than 5% nuclear
expression, loss of SATB1 expression (5%) occurred in
52.3% of NSCLC tumors compared with 6% of normal tissue
specimens. In SCLCs, there was no statistical difference in
the level or frequency of SATB1 nuclear expression between
tumors and the normal bronchial tissue specimens (Figure 2M),
and no significant difference in clinicopathological characteris-
tics (Table 2). Loss of nuclear SATB1 expression was more
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FIGURE 1. Differential special AT-rich binding
protein 1 (SATB1) expression in normal lung
and lung cancer cell lines. The normal bron-
chial epithelial cell line NL20 (blue) was com-
pared with non-small cell lung cancer (NSCLC)
cell lines (red); H520, p  0.010 (squamous
cell carcinoma); H358, p  0.032 (bronchi-
oloalveolar); H1975, p  0.001 (adenocarci-
noma [ADC]); H460, p  0.042 (large cell car-
cinoma); A427, p  0.004 (ADC); A549, p 
0.001 (ADC); H292, p  0.152 (mucoepider-
moid carcinoma); H1299, p  0.144 (meta-
static NSCLC); and a small cell lung cancer cell
line (SCLC; green; p  0.022) at the messen-
ger RNA (mRNA) level by quantitative poly-
merase chain reaction (qPCR, normalized to
Glyceraldehyde 3-phosphate dehydrogenase
[GAPDH]) (A). Relative protein levels (B) were
compared between the NL20 (blue); NSCLC
cell lines (red; H520, p  0.014; H358, p 
0.006; H1975, p  0.028; H460, p  0.009;
A427, p  0.044; A549, p  0.374; H292, p 
0.403; H1299, p  0.239); and SCLC cell line
(green; p  0.001). The breast cancer cell line
MDA-MB-231 (yellow) was included as a posi-
tive control (A, p  0.032; B, p  0.066). *De-
fines significance 0.05 relative to normal
NL20, NS, not significant. Error bars represent
standard error of the mean. Representative
Western blot (C) showing SATB1 (lower band)
and GAPDH.
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frequent in ADC tumors than in SCC (p 0.001) or LCC (p
0.005) (Table 1). In NSCLCs, SATB1 expression (5%) was
associated with poor differentiation (p  0.019) (Table 1). In
early stages of NSCLC, such as stage 1A, the majority of cases
were SATB1 positive (p  0.041) (Table 1). In contrast, the
majority of stage 3 and stage 4 tumors were SATB1 negative,
but this was not statistically significant (p  0.106).
We observed no significant difference in the expression
of nuclear SATB1 in normal bronchial epithelial cells from
patients with NSCLC with or without a history of smoking
(p  0.371). Of the 10 never smokers, 50% displayed loss of
SATB1 expression in tumor tissue, which was the same
frequency as patients who were current smokers (Table 1,
p  0.854). There was also no significant difference in SATB1
expression between tumor tissue from patients who had never
smoked or had ever smoked (p 1.000). The majority of never
smokers had ADC (27%) or BAC (55%).
Cytoplasmic staining of SATB1 (data not shown) was
also observed, but only 0.8% of cells stained positive in the
normal bronchial epithelium. In contrast to the decrease in
nuclear expression in NSCLCs, the level of cytoplasmic expres-
sion of SATB1 was increased in NSCLCs (p  0.001). The
percentage of cells staining positive for SATB1 was 7.4% for
LCC, 29.4% for SCC, 9.3% for ADC, and 14.0% for NSCLC
metastatic lymph node tumors. Nevertheless, cytoplasmic
SATB1 expression was not associated with survival or any other
clinicopathological parameters. Only 1.7% of cells in SCLCs
showed cytoplasmic SATB1 expression, and this was not signifi-
cantly different from normal bronchial epithelium (p  0.510).
Loss of Nuclear SATB1 Expression is an Early
Event in SCC
Lung cancers have been reported to arise from a series
of progressive pathological lesions.35–37 Preinvasive changes
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FIGURE 2. Immunohistochemistry analysis of
special AT-rich binding protein 1 (SATB1) expres-
sion in tumor samples. SATB1 was expressed in
normal bronchial epithelial cells (A) but not in pe-
ripheral lung alveoli (D). SATB1 stained positively
in T lymphocytes in spleen tissue (G) and stained
positively in breast tumors (J). Representative
staining is also shown for SATB1 expression in ad-
enocarcinoma (ADC) 5% (B) and 5% (C), in
squamous cell carcinoma (SCC) 5% (E) and
5% (F), in large cell carcinoma (LCC) 5% (H)
and 5% (I) and in small cell lung cancer (SCLC)
5% (K) and 5% (L). Scale  500 m. SATB1
expression (M) was compared with normal bron-
chial epithelium in SCLCs (p  0.574), SCLC me-
tastases (p  0.380), LCC (p  0.001), SCC (p 
0.001), ADC (p  0.001), and NSCLC metastases
(p  0.001). *Defines significance 0.001 relative
to normal. NS, not significant. Error bars repre-
sent standard error of the mean.
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have been well defined for SCC, whereas preinvasive changes
leading to ADC or LCC are less well understood.4,38,39 We
wanted to determine whether loss of SATB1 expression oc-
curred before invasive SCC tumor formation, and if so, at which
preinvasive stage this could be detected. We observed a signif-
icant reduction in the average level of SATB1 nuclear expres-
sion in all categories of preinvasive squamous lesions analyzed
(Figure 3A), including squamous metaplasia (p 0.001) (Figure
3C), low-grade dysplasia (p  0.001) (Figure 3D), and carci-
noma in situ (p  0.04) (Figure 3E), along with SCC (p 
0.001) (Figure 3F), carcinoma in situ (p  0.042), and lymph
node metastasis (p 0.001) (Figure 3G), compared with normal
bronchial expression (Figure 3B). This suggests that loss of SATB1
expression is an early event in squamous cell carcinogenesis and is
detectable in the most initial stage of preinvasive changes.
Loss of SATB1 Expression is Associated with
Poorer Survival in SCC and in Patients with
NSCLC with History of Smoking
Significance of SATB1 expression for disease-specific
survival was assessed (Figure 4). Noncancer-related deaths
and patients who were still alive at the time of analysis were
TABLE 1. Clinicopathological Characteristics and SATB1
Nuclear Expression in NSCLCs
SATB1 Negative
(<5% Expression)
SATB1 Positive
(>5% Expression) p
Pathology
Well differentiated 16 (62%) 10 (38%) 0.100
Moderately
differentiated
56 (52%) 51 (48%) 0.244
Poorly differentiated 44 (40%) 66 (60%) 0.019
Histology type
SCC (vs. total
tumors)
29 (33%) 58 (67%) 0.001
ADC (vs. total
tumors)
68 (64%) 39 (36%) <0.001
LCC (vs. total
tumors)
19 (39%) 30 (61%) 0.200
ADC vs. SCC — — <0.001
ADC vs. LCC — — 0.005
SCC vs. LCC — — 0.577
AJCC stage
1A 18 (35%) 34 (65%) 0.041
1B 46 (49%) 48 (51%) 0.793
2A 4 (33%) 8 (67%) 0.382
2B 37 (54%) 31 (46%) 0.202
3A 3 (75%) 1 (25%) 0.351
3B 3 (43%) 4 (57%) 1.000
4 5 (83%) 1 (17%) 0.106
Smoking history
Current smokers 17 (50%) 17 (50%) 0.854
Exsmoker 70 (47%) 79 (53%) 0.793
Never smoked 5 (50%) 5 (50%) 1.000
Unknown 24 (48%) 26 (52%) 1.000
Lymphatic invasion
Absent 97 (48%) 105 (52%) 0.866
Present 19 (46%) 22 (54%) 0.866
Blood vessel invasion
Absent 94 (48%) 100 (52%) 0.749
Present 22 (45%) 27 (55%) 0.749
Perineural invasion
Absent 104 (47%) 119 (53%) 0.350
Present 12 (60%) 8 (40%) 0.350
Pleural invasion
Absent 86 (48%) 93 (52%) 0.885
Present 30 (47%) 34 (53%) 0.885
Bronchial resection
margin
Not involved 106 (47%) 120 (53%) 0.452
Involved 10 (59%) 7 (41%) 0.452
Clinicopathological characteristics were compared between patients with SATB1-
negative tumors (5%) and SATB1-positive tumors (5%) in non-small cell lung
cancers (NSCLC) Bolded values denote statistically significant p value.
SCC, squamous cell carcinoma; ADC, adenocarcinoma; LCC, large cell carcinoma;
SATB1, special AT-rich binding protein 1; AJCC, American Joint Committee on Cancer.
TABLE 2. Clinicopathological Characteristics and SATB1
Nuclear Expression in SCLCs
SATB1 Negative
(<5% Expression)
SATB1 Positive
(>5% Expression) p
Pathology
Poorly differentiated 2 (14%) 12 (86%) N/A
AJCC stage
1A 0 (0%) 3 (100%) 1.000
1B 0 (0%) 2 (100%) 1.000
2A 0 (0%) 0 (0%) N/A
2B 0 (0%) 1 (100%) 1.000
3A 1 (25%) 4 (75%) 1.000
3B 1 (33%) 2 (67%) 0.396
4 0 (0%) 0 (0%) N/A
Smoking history
Current smokers 0 (0%) 2 (100%) 0.533
Exsmokers 0 (0%) 0 (0%) N/A
Never smoked 0 (0%) 1 (100%) 0.672
Unknown 2 (18%) 9 (82%) 0.425
Lymphatic invasion
Absent 2 (14%) 12 (86%) N/A
Present 0 (0%) 0 (0%) N/A
Blood vessel invasion
Absent 1 (9%) 10 (91%) 0.396
Present 1 (33%) 2 (67%) 0.396
Perineural invasion
Absent 2 (14%) 12 (86%) N/A
Present 0 (0%) 0 (0%) N/A
Pleural invasion
Absent 2 (15%) 11 (85%) 1.000
Present 0 (0%) 1 (100%) 1.000
Bronchial resection
margin
Not involved 2 (14%) 12 (86%) N/A
Involved 0 (0%) 0 (0%) N/A
Clinicopathological characteristics were compared between patients with SATB1-
negative tumors (5%) and SATB1-positive tumors (5%) in small cell lung cancers
(SCLC).
N/A, not applicable; AJCC, American Joint Committee on Cancer; SATB1, special
AT-rich binding protein 1.
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censored resulting in 152 patients with NSCLC and 9 patients
with SCLC. Loss of SATB1 expression was associated with
poorer survival in the patients with NSCLC who had ever
smoked (p 0.049) but not in the whole NSCLC cohort (p
0.09). In the NSCLC subgroups, loss of SATB1 expression
was significantly associated with decreased disease-specific
survival in SCC (p  0.01) but not in LCC (p  0.40) or
ADC (p  0.23). In patients with SCLC, loss of SATB1
expression also correlated with poorer disease-specific sur-
vival (p  0.03). Nevertheless, after censoring, the SATB1-
negative group contained only two patients of a total nine
patients; therefore, this survival difference requires validation
with a larger sample group.
In a multivariate analysis, loss of SATB1 expression was
found to be an adverse prognostic factor in SCCs, independent
of AJCC stage, lymphatic, and blood vessel invasion (HR: 2.06,
95% CI: 1.2–3.7, p 0.016) (Table 3). In patients with NSCLC
who had ever smoked, loss of SATB1 expression was not an
independent prognostic factor (HR: 1.41, 95%CI: 0.9–2.15, p
0.114) (Table 3).
SATB1 Expression is Epigenetically Regulated
in Lung Cancer Cell Lines
In a study of 11 lung carcinoma samples in the Cosmic
cancer database,40 SATB1 mutations were found to be very
rare, with only one single point mutation in one of the 11
samples investigated. Similarly, mutations in SATB1 ap-
peared to be rare in all other cancer tissue types. Therefore,
we began by examining whether loss of SATB1 expression
was due to epigenetic silencing. Two lung cancer cell lines
(H520 and A549) were treated with the demethylating agent
5-AzaC, an inhibitor of histone deacetylase—TSA, or a
combination of both. We observed an increase in expression
of SATB1 in both H520 and A549 cell lines, after 200 nM
TSA treatment alone (p  0.01, p  0.03) and a further
increase in expression in cells treated with both 5 M 5-AzaC
and 200 nM TSA (p  0.01 and p  0.01), suggesting that
SATB1 expression is epigenetically repressed in these lung
cancer cell lines (Figures 5A, B).
To determine whether the down-regulation of SATB1
was associated with chromatin remodeling, we performed
ChIP on the SCC cell line NCI-H520 and the normal bron-
chial epithelial cell line NL20. NCI-H520 cells express
SATB1 at low levels, compared with the NL20 cells where
SATB1 expression is at moderately high levels (Figure 1A).
In the NCI-H520 cells, the SATB1 promoter was found to be
deacetylated at histone H3K9 (Figure 5C) relative to the
NL20 cell line. Furthermore, in the NCI-H520 cells, SATB1
was significantly enriched for the repressive chromatin mark
35
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FIGURE 3. Immunohistochemistry analysis of
special AT-rich binding protein 1 (SATB1) ex-
pression in normal lung and preneoplastic le-
sions. A, SATB1 expression was analyzed by
immunohistochemistry and found to be signifi-
cantly lost in squamous metaplasia (p 
0.001), low-grade squamous dysplasia (p 
0.001), carcinoma in situ (p  0.04), squa-
mous cell carcinoma (p  0.001), carcinoma in
situ (P  0.042) and squamous lymph node
metastasis compared with normal bronchial
epithelial cells compared. *Denotes p  0.05
significance relative to normal. Error bars repre-
sent standard error of the mean. Representa-
tive staining is shown for normal bronchial epi-
thelium (B), squamous metaplasia (C),
squamous low grade dysplasia (D), squamous
cell carcinoma in situ (E), squamous cell carci-
noma (F), and squamous cell lymph node me-
tastasis (G). Scale  500 m.
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trimethylated histone H3 lysine 27 (H3K27Me3) relative to
the NL20 cells (Figure 5C). SATB1 is, therefore, silenced
by deacetylation of histone H3K9 with enrichment of
H3K27Me3 in NCI-H520 cells, suggesting that chromatin
remodeling is associated with the down-regulation of
SATB1.
DISCUSSION
SATB1 is a cell-type-specific nuclear protein and plays
an active role in higher-order chromatin organization that
regulates gene expression, and it is essential for normal T-cell
development.41 SATB1 tethers loops of DNA to the nuclear
matrix, recruiting chromatin-remodeling factors that play an
important role in modifying gene expression.7 SATB1 can act
as a transcriptional activator or a repressor, by recruiting
other transcriptional activators or repressors, depending on
the specific genomic sites of SATB1 binding. In the breast
cancer cell line MDA-MB-231, SATB1 binding to specific
regions leads to recruitment of histone acetylases (such as
p300) and results in up-regulation of specific SATB1 bound
genes.10 In thymocytes and MDA-MB-231 cells, SATB1 also
facilitates histone deacetylase 1 binding and consequent re-
pression of other genes.10,11 Recently, it was shown in breast
cancer that SATB1 directly up-regulates metastasis-associ-
ated genes10 and is involved in multidrug resistance,42 with
higher expression levels also correlating with shorter overall
survival times.10 High expression of SATB1 is also associ-
ated with poor overall survival in gastric cancers.19,20 Nev-
ertheless, these studies have not been independently vali-
dated,12–14 and one study found increased SATB1 expression
corresponded with improved disease-free survival in estrogen
receptor-positive patients with breast cancer.13 Regardless of
this dichotomy, by its role as a “genome organizer,” SATB1
is thought to potentially play a key role in cancer progression,
deserving of further investigations.
We have shown for the first time that SATB1 is
expressed in the normal bronchial epithelial cells of the lung
but is significantly reduced or lost in NSCLCs, based on
immunohistochemical analysis of resected tumors and West-
ern blot and qPCR analysis in lung cancer cell lines. SATB1
is significantly reduced in early squamous neoplastic prein-
vasive lesions and in SCCs and lymph node metastases.
Although squamous metaplasia is considered reversible,
squamous dysplasias and carcinoma in situ are most fre-
quently associated with progression to SCC.35,38 Our finding
suggests that cells of the bronchial epithelium undergo sig-
A B
C D
FIGURE 4. Disease-specific survival and special AT-rich binding protein 1 (SATB1) expression in patients with lung cancer.
Kaplan-Meier analyses for lung cancer-specific survival stratified by SATB1 expression in non-small cell lung cancer (A), small
cell lung cancer (B), squamous cell lung cancer (C), and patients with non-small cell lung cancer who had ever smoked (D).
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nificant loss of SATB1 expression early during squamous
carcinogenesis, and this can be detected in the most initial
preneoplastic lesions.
Our studies reveal that loss of SATB1 expression is a
significant adverse prognostic factor in SCCs, independent of
tumor stage and lymphatic metastatic invasion. SCCs usually
arise centrally in the lung and are thought to derive from cells
of the major bronchi.43 This may explain why loss of SATB1
expression is pertinent to SCCs and not to ADCs, which are
thought to derive from cells of the peripheral alveoli,44–46
where SATB1 expression is absent. If SATB1 expression in
ADCs was compared with peripheral alveoli rather than the
bronchus, SATB1 could be seen as significantly overex-
pressed, such as in breast, gastric, and laryngeal cancer.
Nevertheless, regardless of which normal tissue SATB1 ex-
pression is compared with in ADC, it was not prognostically
significant in these patients. Despite primary SCLCs showing
on average, no significant difference in SATB1 expression
compared with normal bronchial epithelium, those patients
with SCLC with loss of SATB1 expression still suffered
significantly worse survival outcomes (p  0.03). Further
investigation into the prognostic value of SATB1 in a larger
sample population of SCLCs is warranted.
The phenotypically “normal” small airway epithelium
of smokers has been shown to have approximately 300 genes
up- or down-regulated compared with normal airway epithe-
lium of nonsmokers.47 We compared normal tissue from
smokers and nonsmokers and observed no significant differ-
ence in the expression of SATB1 in normal bronchial epithe-
lial cells from patients with or without a history of smoking.
Interestingly, although SATB1 is a master epigenetic
regulator of gene expression, we show that the SATB1 gene
itself is epigenetically regulated through histone modifica-
tions in a SCC cell line. In SCC cells, we show that SATB1
is enriched for the repressive chromatin mark trimethylated
H3K27 with moderate deacetylation of the active chromatin
mark histone H3K9 compared with the normal cell line. This
TABLE 3. Multivariate Analysis of SATB1 and
Clinicopathological Parameters
Variable
Hazard
Ratio
95%
Confidence
Interval p
Squamous cell
carcinoma
Univariate SATB1 negative 2.28 1.32–3.95 0.004
AJCC stage 1.81 1.23–2.68 0.005
Lymphatic invasion 4.45 2.40–8.26 <0.001
Blood vessel invasion 5.10 2.73–9.56 <0.001
Multivariate SATB1 negative 2.06 1.15–3.72 0.016
AJCC stage 1.47 0.75–2.88 0.263
Lymphatic invasion 2.65 1.09–6.43 0.031
Blood vessel invasion 1.96 0.80–4.83 0.142
(NSCLC) Ever
smoked
Univariate SATB1 negative 1.48 0.998–2.20 0.050
AJCC stage 1.80 1.36–2.40 <0.001
Lymphatic invasion 3.12 1.86–5.24 <0.001
Blood vessel invasion 2.15 1.21–3.79 0.016
Multivariate SATB1 negative 1.41 0.92–2.15 0.114
AJCC stage 1.93 1.21–3.07 0.006
Lymphatic invasion 2.70 1.43–3.10 0.002
Blood vessel invasion 1.05 0.51–2.16 0.887
Univariate and multivariate analyses were performed using Cox proportional hazard
model in squamous cell carcinomas and in patients with non-small cell lung cancer
(NSCLC) who had ever smoked. Bolded values denote statistically significant p value.
AJCC, American Joint Committee on Cancer; SATB1, special AT-rich binding
protein 1.
FIGURE 5. Epigenetic regulation of special AT-rich binding
protein 1 (SATB1). A, In the squamous cell line NCI-H520,
SATB1 messenger RNA (mRNA) expression was significantly
increased in cells treated with 50 nM trichostatin A (TSA)
(p  0.024), 100 nM TSA (p  0.021), 200 nM TSA (p 
0.001), and 5 M 5-Aza-2-deoxycytidine (5-AzaC)  200
nM TSA (p  0.001). B, In the adenocarcinoma cell line
A549, SATB1 mRNA expression was significantly increased in
cells treated with 5 M 5-AzaC (p  0.010), 50 nM TSA
(p  0.025), 200 nM TSA (p  0.031), and 5 M 5-AzaC 
200 nM TSA (p  0.001). *Denotes p  0.05 compared
with mock control. Expression was quantitated by real-time
polymerase chain reaction (PCR) and normalized using
GAPDH expression. C, Chromatin immunoprecipitation was
performed on NL20 and NCI-H520 cells using H3K9Ac (ac-
tive mark) and H3K27Me3 (repressive mark) antibodies. The
amount of immunoprecipitated DNA (relative binding) was
quantitated by real-time PCR and was calculated as a ratio of
immunoprecipitated DNA relative to internal control genes:
GAPDH (H3K9Ac) and MyoD (H3K27Me3). Data are shown
relative to normal NL20. *Denotes p  0.05 compared with
NL20. Error bars represent standard error of the mean.
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silencing is reversed on inhibition of histone deacetylase
using TSA. Therefore, we speculate that loss of SATB1
expression in primary SCC lung tumors may also be con-
trolled by epigenetic silencing mechanisms. Further studies
are needed to determine whether this epigenetic silencing
phenomenon is widespread in SCCs. Chromatin modifica-
tions such as loss of histone H4K16 acetylation and histone
H4K20 trimethylation have been detected in lymphomas,
liver, breast, and colon cancers.48 In lung tumorigenesis,
global loss of H4K20 trimethylation correlates with poor
survival.5 Clearly aberrant modification of histones plays a
significant role in cancer development.
Through its role as an epigenetic regulator, both over-
activation and loss of SATB1 function is expected to have
widespread genomic consequences. SATB1 orchestrates the
epigenetic organization of multiple genes by region-specific
histone modifications, by recruiting proteins such as HDAC 1
and 2, histone acetylase p300, and imitation switch ATPase
(ISWI).7,10,11 Apart from the profound effect of SATB1
up-regulation on tumorigenesis, loss of SATB1 function may
also be critical because it causes widespread disruption of
histone modifications. These may result in the loss of activa-
tion or loss of repression of other genes, which contribute to
tumorigenesis. In contrast with several studies in other can-
cers,10,19–21 where SATB1 is absent in normal tissue, and the
aberrant expression of SATB1 correlates with tumor progres-
sion and poor survival, in lung cancer the reverse is observed.
There is currently no data indicating the specific role of
SATB1 in bronchial epithelial cells of the lung. The bronchial
epithelium functions as a barrier to inhaled environmental
particulates supported by ciliated and secretory cells. The
airway epithelium undergoes constant renewal and responds
quickly to injury with ongoing dedifferentiation and prolif-
eration.49 An explanation for the opposing findings of SATB1
expression in different tissues could be in the role of SATB1
as a differentiation gene in normal bronchial cells, similar to
its role in T cells, where it is required for normal cell
development. The SATB1 null mouse has multiple defects in
T cells at every stage of development and is not viable
beyond 3 weeks of age.41 SATB1 functions to coordinate
gene expression for T-cell development and maturation. We
speculate that if SATB1 is acting in a similar way in the lung,
to coordinate gene expression for normal bronchial cell main-
tenance, then it is conceivable that loss of a key differentia-
tion gene may stall precursor cells in a less differentiated and
more pluripotent state that renders them more tumorigenic.
SATB1 has also been shown to play a role in stem-cell
differentiation and deregulation of pluripotency. SATB1 neg-
atively regulates the pluripotency genes Nanog, Klf4, and
Tbx3 in mouse embryonic stem cells and is required for
proper stem-cell differentiation.50 In SATB1 null embryonic
stem cells, Nanog expression is elevated, resembling cells
where self-renewal is strongly favored over differentiation.50
In the context of the lung, SATB1 could also be important for
the balance between differentiation and pluripotency in a
tissue environment undergoing rapid repair. Further investi-
gations are needed to explore the functional role of SATB1 in
the bronchial epithelium.
In conclusion, loss of SATB1 expression is a prognos-
tically significant factor in tumors derived from bronchial
epithelial cells, such as SCCs. Loss of SATB1 expression
may have profound biologic consequences because of the
epigenetic deregulation of hundreds of genes at once. The
potency of SATB1 to potentially affect the regulation of up
to 10% of the genome may help explain why it is a strong
prognostic marker, independent of the most established
predictive factors in lung cancer, and also may explain
why it can be both a positive and negative marker in
cancers from different tissues. Investigation into SATB1
target genes in the context of lung cancer could help
stratify patients in terms of prognosis, and justifies further
research, opening up new avenues for the study of lung
cancer treatment and chemoprevention.
ACKNOWLEDGMENTS
Supported by the Cancer Institute NSW (Grants 09/
RIG/1-18 and 09/RIG/1-03), Australian Cancer Research
Foundation (2010), the Garvan Research Foundation and RT
Hall Trust. M.R.J.K. is a Cancer Institute NSW Career
Development Fellow (07/CDF/1-19).
REFERENCES
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J
Clin 2006;56:106–130.
2. Shibuya K, Mathers CD, Boschi-Pinto C, et al. Global and regional
estimates of cancer mortality and incidence by site: II. Results for the
global burden of disease 2000. BMC cancer 2002;2:37.
3. Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest
1997;112:251S–258S.
4. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu Rev Pathol
2006;1:331–348.
5. Van Den Broeck A, Brambilla E, Moro-Sibilot D, et al. Loss of histone
H4K20 trimethylation occurs in preneoplasia and influences prognosis
of non-small cell lung cancer. Clin Cancer Res 2008;14:7237–7245.
6. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifi-
cations predict prognosis of resected non small-cell lung cancer. J Clin
Oncol 2007;25:4358–4364.
7. Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architec-
ture and gene expression regulated by SATB1. Nat Genet 2003;34:
42–51.
8. de Belle I, Cai S, Kohwi-Shigematsu T. The genomic sequences bound
to special AT-rich sequence-binding protein 1 (SATB1) in vivo in Jurkat
T cells are tightly associated with the nuclear matrix at the bases of the
chromatin loops. J Cell Biol 1998;141:335–348.
9. Dickinson LA, Joh T, Kohwi Y, et al. A tissue-specific MAR/SAR
DNA-binding protein with unusual binding site recognition. Cell 1992;
70:631–645.
10. Han HJ, Russo J, Kohwi Y, et al. SATB1 reprogrammes gene expression
to promote breast tumour growth and metastasis. Nature 2008;452:187–
193.
11. Yasui D, Miyano M, Cai S, et al. SATB1 targets chromatin remodelling
to regulate genes over long distances. Nature 2002;419:641–645.
12. Patani N, Jiang W, Mansel R, et al. The mRNA expression of SATB1
and SATB2 in human breast cancer. Cancer Cell Int 2009;9:18.
13. Hanker LC, Karn T, Mavrova-Risteska L, et al. SATB1 gene expression
and breast cancer prognosis. Breast. In press. DOI:10.1016/
j.breast.2010.10.002.
14. Iorns E, Hnatyszyn HJ, Seo P, et al. The role of SATB1 in breast cancer
pathogenesis. J Natl Cancer Inst 2010;102:1284–1296.
15. Galande S, Dickinson LA, Mian IS, et al. SATB1 cleavage by caspase
6 disrupts PDZ domain-mediated dimerization, causing detachment
from chromatin early in T-cell apoptosis. Mol Cell Biol 2001;21:5591–
5604.
Selinger et al. Journal of Thoracic Oncology • Volume 6, Number 7, July 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1188
16. Purbey PK, Singh S, Kumar PP, et al. PDZ domain-mediated dimeriza-
tion and homeodomain-directed specificity are required for high-affinity
DNA binding by SATB1. Nucl Acids Res 2008;36:2107–2122.
17. Purbey PK, Singh S, Notani D, et al. Acetylation-dependent interaction
of SATB1 and CtBP1 mediates transcriptional repression by SATB1.
Mol Cell Biol 2009;29:1321–1337.
18. Pavan Kumar P, Purbey PK, Sinha CK, et al. Phosphorylation of
SATB1, a global gene regulator, acts as a molecular switch regulating its
transcriptional activity in vivo. Mol Cell 2006;22:231–243.
19. Cheng C, Lu X, Wang G, et al. Expression of SATB1 and heparanase in
gastric cancer and its relationship to clinicopathologic features. APMIS
2010;118:855–863.
20. Lu X, Cheng C, Zhu S, et al. SATB1 is an independent prognostic
marker for gastric cancer in a Chinese population. Oncol Rep 2010;24:
981–987.
21. Zhao XD, Ji WY, Zhang W, et al. Overexpression of SATB1 in
laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec
2010;72:1–5.
22. Baguma-Nibasheka M, Angka HE, Inanlou MR, et al. Microarray
analysis of Myf5-/-:MyoD-/- hypoplastic mouse lungs reveals a profile
of genes involved in pneumocyte differentiation. Histol Histopathol
2007;22:483–495.
23. Zhou LY, Liu F, Tong J, et al. [Expression of special AT-rich sequence-
binding protein mRNA and its clinicopathological significance in non-
small cell lung cancer]. Nan fang yi ke da xue xue bao J Southern Med
Univ 2009;29:534–537.
24. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict
survival of patients with lung adenocarcinoma. Nat Med 2002;8:816–824.
25. Stearman RS, Dwyer-Nield L, Zerbe L, et al. Analysis of orthologous
gene expression between human pulmonary adenocarcinoma and a
carcinogen-induced murine model. Am J Pathol 2005;167:1763–1775.
26. Talbot SG, Estilo C, Maghami E, et al. Gene expression profiling allows
distinction between primary and metastatic squamous cell carcinomas in
the lung. Cancer Res 2005;65:3063–3071.
27. Tai AL, Mak W, Ng PK, et al. High-throughput loss-of-heterozygosity
study of chromosome 3p in lung cancer using single-nucleotide poly-
morphism markers. Cancer Res 2006;66:4133–4138.
28. Hung J, Kishimoto Y, Sugio K, et al. Allele-specific chromosome 3p
deletions occur at an early stage in the pathogenesis of lung carcinoma.
JAMA 1995;273:558–563.
29. Liu Z, Zhao J, Chen XF, et al. CpG island methylator phenotype
involving tumor suppressor genes located on chromosome 3p in non-
small cell lung cancer. Lung Cancer 2008;62:15–22.
30. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome
3p allelotyping of human lung cancer and preneoplastic/preinvasive
bronchial epithelium reveals multiple, discontinuous sites of 3p allele
loss and three regions of frequent breakpoints. Cancer Res 2000;60:
1949–1960.
31. Seng TJ, Currey N, Cooper WA, et al. DLEC1 and MLH1 promoter
methylation are associated with poor prognosis in non-small cell lung
carcinoma. Br J Cancer 2008;99:375–382.
32. Abramoff MD. Image processing with ImageJ. Biophoton Int 2004;11:
36–42.
33. Sobin L. TNM Classification of Malignant Tumours. New York: Wiley-
Liss, 2002.
34. Lung. In Edge SB, Byrd DR, Comptom CC, et al. American Joint
Committee on Cancer. AJCC Cancer Staging Manual. New York, NY:
Springer, 2010:253–270.
35. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithe-
lium in relation to cigarette smoking, 1955–1960 vs. 1970–1977. N Engl
J Med 1979;300:381–385.
36. Gazdar AF. The molecular and cellular basis of human lung cancer.
Anticancer Res 1994;14:261–267.
37. Jeanmart M, Lantuejoul S, Fievet F, et al. Value of immunohistochem-
ical markers in preinvasive bronchial lesions in risk assessment of lung
cancer. Clin Cancer Res 2003;9:2195–2203.
38. Greenberg AK, Yee H, Rom WN. Preneoplastic lesions of the lung.
Respir Res 2002;3:20.
39. Lantuejoul S, Salameire D, Salon C, et al. Pulmonary preneoplasia—
sequential molecular carcinogenetic events. Histopathology 2009;54:
43–54.
40. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic
mutations in cancer (COSMIC). In Haines JL, Korf BR, Morton CC, et
al. (Eds.), Current protocols in human genetics/editorial board. Chapter
10:Unit 10 11, 2008.
41. Alvarez JD, Yasui DH, Niida H, et al. The MAR-binding protein SATB1
orchestrates temporal and spatial expression of multiple genes during
T-cell development. Genes Dev 2000;14:521–535.
42. Li QQ, Chen ZQ, Xu JD, et al. Overexpression and involvement of
special AT-rich sequence binding protein 1 in multidrug resistance in
human breast carcinoma cells. Cancer Sci 101:80–86.
43. Wistuba II. Histologic evaluation of bronchial squamous lesions: any
role in lung cancer risk assessment? Clin Cancer Res 2005;11:1358–
1360.
44. Barbone F, Bovenzi M, Cavallieri F, et al. Cigarette smoking and
histologic type of lung cancer in men. Chest 1997;112:1474–1479.
45. Khuder SA. Effect of cigarette smoking on major histological types of
lung cancer: a meta-analysis. Lung Cancer 2001;31:139–148.
46. Sobue T, Yamamoto S, Hara M, et al. Cigarette smoking and subsequent
risk of lung cancer by histologic type in middle-aged Japanese men and
women: the JPHC study. Int J Cancer 2002;99:245–251.
47. Harvey BG, Heguy A, Leopold PL, et al. Modification of gene expres-
sion of the small airway epithelium in response to cigarette smoking.
J Mol Med 2007;85:39–53.
48. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at
Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark
of human cancer. Nat Genet 2005;37:391–400.
49. Crystal RG, Randell SH, Engelhardt JF, et al. Airway epithelial cells:
current concepts and challenges. Proc Am Thorac Soc 2008;5:772–777.
50. Savarese F, Davila A, Nechanitzky R, et al. Satb1 and Satb2 regulate
embryonic stem cell differentiation and Nanog expression. Genes Dev
2009;23:2625–2638.
Journal of Thoracic Oncology • Volume 6, Number 7, July 2011 SATB1 is a Prognostic Marker in Lung Cancer
Copyright © 2011 by the International Association for the Study of Lung Cancer 1189
